Detrol Side Effects
Generic Name: tolterodine
Note: This page contains information about the side effects of tolterodine. Some of the dosage forms included on this document may not apply to the brand name Detrol.
Not all side effects for Detrol may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to tolterodine: oral capsule extended release, oral tablet
In addition to its needed effects, some unwanted effects may be caused by tolterodine (the active ingredient contained in Detrol). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking tolterodine:More common
- Abnormal vision, including difficulty with adjusting to distances
- bloody or cloudy urine
- difficult, burning, or painful urination
- frequent urge to urinate
- Chest pain
- general feeling of discomfort or illness
- joint pain
- loss of appetite
- muscle aches and pains
- pain or tenderness around the eyes and cheekbones
- shortness of breath or troubled breathing
- sore throat
- stuffy or runny nose
- tightness of the chest or wheezing
- trouble with sleeping
- Being forgetful
- bloating or swelling of the face, arms, hands, ankles, lower legs, or feet
- confusion about identity, place, and time
- difficulty with swallowing
- fast, pounding, or irregular heartbeat or pulse
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- mood or mental changes
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- rapid weight gain
- seeing, hearing, or feeling things that are not there
- skin rash
- tingling of the hands or feet
- unusual tiredness or weakness
- unusual weight gain or loss
Some of the side effects that can occur with tolterodine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Abdominal or stomach pain
- dry eyes
- dry mouth
- upset stomach
- Acid or sour stomach
- blurred vision
- difficulty with moving
- dizziness or lightheadedness
- dry skin
- fear or nervousness
- feeling of constant movement of self or surroundings
- sensation of spinning
- sleepiness or unusual drowsiness
- stomach discomfort
- weight gain
For Healthcare Professionals
Applies to tolterodine: oral capsule extended release, oral tablet
General side effects reported during postmarketing experience have included hallucinations. Most of the side effects of tolterodine (the active ingredient contained in Detrol) are extensions of its pharmacologic activity and are anticholinergic in nature. In clinical trials, 8% of patients discontinued treatment due to adverse events. Among the most common complaints leading to discontinuation was headache, which occurred in 11% of patients.
Most reports of dry mouth were mild to moderate in intensity. Severe dry mouth was reported during therapy with tolterodine (the active ingredient contained in Detrol) by 1% to 5% of patients in several large, placebo controlled studies.
Gastrointestinal side effects reported the most frequently have included dry mouth (19.7% to 39.5%). Dyspepsia, constipation, abdominal pain, and flatulence have been reported in 1% to 10% of patients. Diarrhea (1.8%), nausea (1.2%), and gastroesophageal reflux (1%) have been reported. Decreased motility and GI hemorrhage have been reported during postmarketing experience.
Ocular side effects have included abnormal or blurred vision (4.7%) and xerophthalmia (3.8%).
Reports of aggravation of symptoms of dementia (e.g., confusion, disorientation, and delusion) have been reported after tolterodine (the active ingredient contained in Detrol) therapy was initiated in patients taking cholinesterase inhibitors for the treatment of dementia.
A 73-year-old female presented with a two-year history of decreased short-term memory and vivid hallucinations of deceased relatives that occurred only during nighttime sleep; she awoke regularly to converse with these relatives. The symptoms began several weeks after taking tolterodine (2 mg twice daily) for urinary incontinence. These hallucinations did not distress the patient and resolved after three months of donepezil treatment. Her memory impairment improved after tolterodine was discontinued for several months. It recurred after tolterodine therapy was restarted.
Nervous system side effects including headache, vertigo or dizziness, and fatigue have been reported in 1% to 10% of patients. Somnolence (0.4% to 10%), asthenia (3.6%), insomnia (0.4% to 1.6%), nervousness (1%), confusion (less than 1%), and hallucinations (less than 1%) have been reported. Syncope, convulsions, disorientation, memory impairment, and aggravation of symptoms of dementia (e.g., confusion, disorientation, and delusion) have been reported during postmarketing experience.
Genitourinary side effects including dysuria (1% to 10%), urinary tract infection (0.4% to 9%), urinary retention (less than 1% to 1.7%), and impaired urination (0.4%) have been reported.
Cardiovascular side effects have infrequently included hypertension or minor increases in heart rate. Peripheral edema has been reported in 1% of patients. Tachycardia, peripheral edema, chest pain, ventricular arrhythmia, atrial fibrillation, cardiac failure, palpitations, bradycardia, collapse, and transient ischemic attacks have been reported during postmarking experience.
Hypersensitivity side effects including allergic reactions have been reported in less than 1% of patients. Anaphylactoid reactions have been reported during postmarketing experience.
Hepatic side effects have rarely included acute mixed liver injury. Hepatic dysfunction has also been reported during postmarketing experience.
Dermatologic side effects including flushed skin have been reported in less than 1% of patients.
Respiratory side effects including bronchitis and sinusitis have been reported in 1% to 10% of patients. Cough (4% to 7%), rhinitis (4% to 7%), sore throat (4% to 7%), respiratory infection (4% to 6%), and influenza (0.4% to 1%) have been reported.
Metabolic side effects including weight gain have been reported in 1% to 10% of patients.
Psychiatric side effects including depression have been reported during postmarketing experience.
Renal side effects including renal dysfunction have been reported during postmarketing experience.
Other side effects including pyrexia have been reported in 4% of patients.
More about Detrol (tolterodine)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.